Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 4
2004 3
2005 2
2006 3
2007 4
2008 4
2009 1
2010 6
2011 6
2012 8
2013 4
2014 3
2015 1
2016 6
2017 3
2018 5
2019 4
2020 13
2021 12
2022 10
2023 7
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Results by year

Filters applied: . Clear all
Page 1
USP7 inhibitors suppress tumour neoangiogenesis and promote synergy with immune checkpoint inhibitors by downregulating fibroblast VEGF.
Jurisic A, Sung PJ, Wappett M, Daubriac J, Lobb IT, Kung WW, Crawford N, Page N, Cassidy E, Feutren-Burton S, Rountree JSS, Helm MD, O'Dowd CR, Kennedy RD, Gavory G, Cranston AN, Longley DB, Jacq X, Harrison T. Jurisic A, et al. Among authors: longley db. Clin Transl Med. 2024 Apr;14(4):e1648. doi: 10.1002/ctm2.1648. Clin Transl Med. 2024. PMID: 38602256 Free PMC article.
Identification of unique rectal cancer-specific subtypes.
Kisakol B, Matveeva A, Salvucci M, Kel A, McDonough E, Ginty F, Longley DB, Prehn JHM. Kisakol B, et al. Among authors: longley db. Br J Cancer. 2024 Mar 26. doi: 10.1038/s41416-024-02656-0. Online ahead of print. Br J Cancer. 2024. PMID: 38532103
Nanoencapsulation of MDM2 Inhibitor RG7388 and Class-I HDAC Inhibitor Entinostat Enhances their Therapeutic Potential Through Synergistic Antitumor Effects and Reduction of Systemic Toxicity.
Abed A, Greene MK, Alsa'd AA, Lees A, Hindley A, Longley DB, McDade SS, Scott CJ. Abed A, et al. Among authors: longley db. Mol Pharm. 2024 Mar 4;21(3):1246-1255. doi: 10.1021/acs.molpharmaceut.3c00926. Epub 2024 Feb 9. Mol Pharm. 2024. PMID: 38334409 Free PMC article.
surviveR: a flexible shiny application for patient survival analysis.
Sessler T, Quinn GP, Wappett M, Rogan E, Sharkey D, Ahmaderaghi B, Lawler M, Longley DB, McDade SS. Sessler T, et al. Among authors: longley db. Sci Rep. 2023 Dec 13;13(1):22093. doi: 10.1038/s41598-023-48894-9. Sci Rep. 2023. PMID: 38086891 Free PMC article.
Health diplomacy in action: The cancer legacy of the Good Friday Agreement.
Lawler M, Sullivan R, Abou-Alfa GK, McCloskey K, Keatley D, Feighan J, Dahut W, Mulroe E, Ladner R, Genead M, Lowery M, Gulley JL, Scott CJ, Longley DB, Culhane A, Gallagher WM, Orr N, Chanock SJ, Gopal S. Lawler M, et al. Among authors: longley db. J Cancer Policy. 2023 Dec;38:100448. doi: 10.1016/j.jcpo.2023.100448. Epub 2023 Oct 14. J Cancer Policy. 2023. PMID: 37839622 Free article.
Editor Profile: Daniel Longley.
FEBS Journal Editorial Team; Longley DB. FEBS Journal Editorial Team, et al. Among authors: longley db. FEBS J. 2024 Feb;291(3):399-401. doi: 10.1111/febs.16898. Epub 2023 Aug 7. FEBS J. 2024. PMID: 37547930
104 results